Sarah S. Lee, M.D.
Sarah Lee, M.D., long dreamed of being a physician, simply because she wanted to help people. She guides her patients in navigating the challenges of treatment, putting a priority on being an active listener. That way, she can understand patients’ goals and empower them to make informed decisions about their treatment.
Dr. Lee is an oncologist/hematologist specializing in plasma-cell disorders such as myeloma and amyloidosis. By the time she joined City of Hope in 2023, she had co-authored 12 peer-reviewed biomedical publications and was site principal investigator for seven active clinical trials. She was previously on the faculty at Fred Hutchinson Cancer Research Center. Before medical school, she served as a clinical research coordinator at a cancer center. Dr. Lee has earned such honors as the Merit Award from the American Society for Clinical Oncology's Conquer Cancer Foundation and an appointment as chief quality improvement fellow during her training at Cleveland Clinic.
Her pastimes include enjoying the outdoors with her two rescue pups, spending time with family and friends, and traveling.
Duarte Cancer Center
Duarte, CA 91010
- 2014, M.D., magna cum laude, distinction in research, St. George's University School of Medicine, Grenada, West Indies
- 2004, B.A., Molecular Cell Biology and Social Welfare, University of California, Berkeley, Berkeley, CA
-
2017-2020, Fellowship, Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
-
2015-2017, Residency, Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ
-
2014-2015, Internship, Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ
- 2023-present, Assistant Clinical Professor, Division of Multiple Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
- 2020-2023, Assistant Professor, Clinician/Scholar Pathway, Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA
- 2020-2023, Assistant Member, Clinical Scholar Pathway, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
- 2020, Cleveland Clinic Graduate Medical Education Patient Safety Day, First Place abstract/poster
- 2019-2020, Chief Quality Improvement Fellow, Cleveland Clinic, Cleveland, OH
- 2019, Conquer Cancer Foundation of ASCO Merit Award
- 2010-2014, Iota Epsilon Alpha International Honor Medical Society, St. George's University, Grenada, West Indies
- 2020-present, SWOG Cancer Research Network
- 2020-present, International Society of Amyloidosis
- 2019-present, International Myeloma Society
- 2017-present, American College of Physicians
- 2017-present, American Society of Hematology
- 2017-present, American Society of Clinical Oncology
- Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling, Rahul Banerjee 1 2, Kara I Cicero 1 2, Sarah S Lee 3, Andrew J Cowan 1 2
- Woolley JD, Gorno-Tempini ML, Seely WW, Rankin K, Lee S, Matthews BR, Miller BL. Binge eating is associated with right-orbitofrontal-insular-striatal atrophy in frontotemporal dementia. Neurology (2007) Oct 2;69(14):1424-33. [original work]
- Patel SD, Peterson A, Bartczak A, Lee S, Chojnowski S, Gajewski P, Loukas M. Primary cardiac angiosarcoma – a review. Med Sci Monit (2014) Jan 23;20:103-9. [review]
- Scott SC, Lee SS, Abraham J. Mechanisms of therapeutic CDK 4/6 inhibition in breast cancer. Seminars in Oncology (2017) Dec;44(6):385-394. [review]
- Barot S, Lee S, Patel B, Valent J. Ibrutinib is effective in refractory type II cryoglobulinemia. Clin Lymphoma Myeloma Leuk (2019) Dec;19(12):e629-e632. [case report]
- Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Adv (2020) Jan 28;4(2):253-262. [original work]
- Durer C, Durer S, Lee S, Chakraborty R, Malik MN, Rafae A, Zar MA, Kamal A, Rosko N, Samaras C, Valent J, Chaulagain C, Anwer F. Treatment of relapsed multiple myeloma: Evidence-based recommendations. Blood Rev (2020) Jan;39:100616. [review]
- Patel BJ, Barot SV, Kuzmanovic T, Kerr C, Przychodzen BP, Thota S, Lee S, Patel S, Radivoyevitch T, Lichtin A, Advani A, Kalaycio M, Sekeres MA, Carraway HE, Maciejewski JP. Distinctive and common features of moderate aplastic anaemia. Br J Haematol [original work] (in press).
- Cowan AJ, Stevenson PA, Green DJ, Tuazon S, Libby EN, Kwok M, Lee S, Coffey DG, Gopal AK, Holmberg LA. Prolonged lenalidomide therapy does not impact autologous peripheral blood stem cell mobilization and collection in multiple myeloma patients: A single-center retrospective analysis. Transplant Cell Therapy. 2021 Apr 22.
- Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and management of multiple myeloma: A review. JAMA. 2022;327(5):464-477.
- Lee S, Cowan AJ. Ciltacabtagene autoleucel. Drugs of the Future. (in press).
- Torkian P, Mansoori B, Hillengass J, Azadbakht J, Rashedi S, Lee SS, Amini B, Bonaffini PA, Chalian M. Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis. Skeletal Radiol. 2022 Jul 26. Epub ahead of print. PMID: 35881152.
- Banerjee R, Lee SS, Cowan AJ. Innovation in BCMA CAR-T therapy: Building beyond the Model T. Front Oncol. 2022 Nov 24;12:1070353. doi: 10.3389/fonc.2022.1070353. PMID: 36505779; PMCID: PMC9729952.